Daniel A. Haber

Oncology
149 13th St
Charlestown, MA 02129

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 134 publications

Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.

Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 17, 2026

Author Correction: HER2 expression identifies dynamic functional states within circulating breast cancer cells.

Author Correction: HER2 expression identifies dynamic functional states within circulating breast cancer cells.

Journal: Nature
Published: April 15, 2026

ATR Safeguards Epithelial-to-Mesenchymal Transition by Countering R-loops and Enabling Transcription Reprogramming.

ATR Safeguards Epithelial-to-Mesenchymal Transition by Countering R-loops and Enabling Transcription Reprogramming.

Journal: The Journal of clinical investigation
Published: January 22, 2026

TMPO promotes cellular dissemination and metastasis in circulating tumor cells.

TMPO promotes cellular dissemination and metastasis in circulating tumor cells.

Journal: bioRxiv : the preprint server for biology
Published: January 09, 2026

Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab.

Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab.

Journal: Cancer discovery
Published: August 25, 2025

The E3 ligase HECTD4 regulates COX-2-dependent tumor progression and metastasis.

The E3 ligase HECTD4 regulates COX-2-dependent tumor progression and metastasis.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 06, 2025

CDKN1B (p27/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors.

CDKN1B (p27/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 07, 2025

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

Journal: The Lancet. Oncology
Published: May 07, 2025

Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications.

Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications.

Journal: Cancer cell
Published: April 22, 2025

Epitope Expression Persists in Circulating Tumor Cells as Breast Cancers Acquire Resistance to Antibody Drug Conjugates.

Epitope Expression Persists in Circulating Tumor Cells as Breast Cancers Acquire Resistance to Antibody Drug Conjugates.

Journal: bioRxiv : the preprint server for biology
Published: April 16, 2025

Combination Diagnostics: Adding Blood-Based ctDNA Screening to Low-Dose CT Imaging for Early Detection of Lung Cancer.

Combination Diagnostics: Adding Blood-Based ctDNA Screening to Low-Dose CT Imaging for Early Detection of Lung Cancer.

Journal: Cancer discovery
Published: September 05, 2024

Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.

Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.

Journal: PloS one
Published: July 01, 2024
Showing 1-12 of 134

Last Updated: 09/26/2026